The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE−/− mice by blocking monocyte/macrophage activation
Why the study?
Does GIP treatment attenuate atherosclerotic plaque inflammation in ApoE-/- mice and abrogate inflammatory macrophage activation?
Population
Patients with atherosclerotic cardiovascular disease, ApoE-/- mice, and in vitro macrophages
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating in murine atherosclerosis; should not change practice pending human trials.
Structured PICO
Does GIP treatment attenuate atherosclerotic plaque inflammation in ApoE-/- mice and abrogate inflammatory macrophage activation?
P
Population
Patients with atherosclerotic cardiovascular disease, ApoE-/- mice, and in vitro macrophages
I
Intervention
GIP treatment
O
Outcome
Atherosclerotic plaque inflammation and inflammatory macrophage activationsurrogate
GIP acts as a counterregulatory vasoprotective peptide that stabilizes atherosclerotic plaques by blocking monocyte/macrophage activation, suggesting potential therapeutic value for high cardiovascular risk patients.
Cite This Study
Kahles et al. (2018) studied this question.